𝐍𝐞𝐰 𝐨𝐧 𝐃𝐫𝐮𝐠 𝐂𝐡𝐚𝐧𝐧𝐞𝐥𝐬: 𝐀𝐮𝐠𝐮𝐬𝐭 2025 𝐍𝐞𝐰𝐬 𝐑𝐨𝐮𝐧𝐝𝐮𝐩 🏖️☀️. Summer’s ending. Time to pack away the bathing suit, send the kids back to school—.and enjoy these curated curiosities from the Drug Channels coastline:. • Aetna’s latest white bagging plan:.

💡 𝐖𝐡𝐲 𝐃𝐨 𝐒𝐢𝐭𝐞-𝐨𝐟-𝐂𝐚𝐫𝐞 𝐏𝐚𝐲𝐦𝐞𝐧𝐭 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞𝐬 𝐏𝐞𝐫𝐬𝐢𝐬𝐭?. Only 47% of health plans and just 32% of employers have adopted site-of-care strategies for provider-administered specialty drugs. This limited uptake—especially by employers—helps

𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐬 𝐬𝐭𝐢𝐥𝐥 𝐠𝐞𝐭 𝐩𝐚𝐢𝐝 𝐧𝐞𝐚𝐫𝐥𝐲 2× 𝐦𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝐨𝐭𝐡𝐞𝐫 𝐬𝐢𝐭𝐞𝐬 𝐨𝐟 𝐜𝐚𝐫𝐞. In 2024, commercial health plans reimbursed:. • Hospital outpatient facilities: 188% of a drug’s ASP plus $472 for administration. • Physician offices: 120% of a

From @kalderos: Solving the Gross-to-Net Bubble with Better Data. Download 𝐅𝐨𝐥𝐥𝐨𝐰𝐢𝐧𝐠 𝐭𝐡𝐞 𝐃𝐨𝐥𝐥𝐚𝐫𝐬: 𝐖𝐡𝐲 340𝐁 𝐑𝐞𝐟𝐨𝐫𝐦 𝐈𝐬 𝐚 𝐃𝐚𝐭𝐚-𝐃𝐫𝐢𝐯𝐞𝐧 𝐍𝐞𝐜𝐞𝐬𝐬𝐢𝐭𝐲: Read the article: #sponsored

𝐓𝐡𝐞 #𝐆𝐫𝐨𝐬𝐬𝐓𝐨𝐍𝐞𝐭𝐁𝐮𝐛𝐛𝐥𝐞 𝐠𝐨𝐞𝐬 𝐠𝐥𝐨𝐛𝐚𝐥! 🌍. @EliLillyandCo is set to raise the list price of Mounjaro in the U.K. But according to the National Health Service, the move won’t affect its costs. Time for SpongeBob SquarePants to renew his passport! 🛂✈️.

For 2024, pharmacy benefit specialty drug spend rose due to claim volume, not prices:. • Claim utilization: +12.9%. • Net cost per claim: -1.7% (driven in part by Humira #biosimilars). • Overall PMPY trend: +11.0%. Full report 👉 Source: 2025

𝐍𝐨𝐭𝐚𝐛𝐥𝐞: 𝐓𝐡𝐞 𝐑𝐢𝐬𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐂𝐡𝐢𝐞𝐟 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐜𝐜𝐞𝐬𝐬 𝐎𝐟𝐟𝐢𝐜𝐞𝐫. Great piece from @RRAonLeadership on why market access has become a strategic priority in biopharma—demanding enterprise-level leadership. “Structurally, the CMAO should be.

Wholesaler vertical integration update: @CardinalHealth $CAH adds Solaris Health (urology MSO) to its specialty portfolio. Wholesalers continue to strengthen their position in buy-and-bill channels for provider-administered drugs by vertical integration with their downstream.

🚨𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐒𝐡𝐚𝐤𝐞𝐨𝐮𝐭: 𝐖𝐡𝐲 𝐔.𝐒. 𝐃𝐫𝐮𝐠𝐬𝐭𝐨𝐫𝐞𝐬 𝐀𝐫𝐞 𝐃𝐢𝐬𝐚𝐩𝐩𝐞𝐚𝐫𝐢𝐧𝐠. In this quick video, I break down 5 powerful economic forces that are reshaping the retail pharmacy landscape—and why it’s getting harder to keep these businesses afloat. 🎥.

ICYMI: The American Medical Association and American Society of Clinical Oncology (ASCO) have released a strongly worded issue brief on a hot drug channel topic: “Mandatory White Bagging and Brown Bagging Policies Threaten Patient Access to Care.”. The brief outlines their

🚨 𝐇𝐮𝐦𝐢𝐫𝐚 𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬: 𝐎𝐮𝐭𝐩𝐞𝐫𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐄𝐱𝐩𝐞𝐜𝐭𝐚𝐭𝐢𝐨𝐧𝐬 (𝐏𝐫𝐨𝐛𝐚𝐛𝐥𝐲). CVS Health’s Cordavis has stopped reporting #Humira biosimilar sales. But a clever new analysis from Bourgoin Insights Group estimates that #biosimilars may hold 14%

Good question from The Wall Street Journal: "America is leading the world into a new era of medical cures and biologic treatments, and the benefits to human health promise to be staggering. Yet why is America’s political class—first Democrats and now Republicans—working hard to.

From @ConnectiveRx: Patient Support’s Perfect Storm in 2025: Hits, Misses, and Surprises. Register for the 9/24 free webinar "𝐁𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐑𝐞𝐬𝐢𝐥𝐢𝐞𝐧𝐭 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐒𝐮𝐩𝐩𝐨𝐫𝐭 𝐖𝐡𝐞𝐧 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐂𝐡𝐚𝐧𝐠𝐞 𝐍𝐞𝐯𝐞𝐫 𝐒𝐭𝐨𝐩𝐬":

🚨 𝐁𝐢𝐠 340𝐁 𝐌𝐚𝐫𝐠𝐢𝐧𝐬 𝐢𝐧 𝐌𝐞𝐝𝐢𝐜𝐚𝐫𝐞 𝐏𝐚𝐫𝐭 𝐁. #340B hospitals acquire Part B single-source drugs at deep discounts but are reimbursed at full Medicare rates. For 200 Part B–covered drugs in 2023:. • Payment by Medicare & beneficiaries = $13.8B . • 340B

𝐒𝐡𝐚𝐝𝐲 𝐀𝐥𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐯𝐞 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐏𝐫𝐨𝐠𝐫𝐚𝐦𝐬 #𝐀𝐅𝐏 𝐒𝐭𝐫𝐢𝐤𝐞 𝐀𝐠𝐚𝐢𝐧!. AFPs often block access to essential biologic therapies, misrepresent patients as uninsured, and create bureaucratic nightmares that delay or deny life-saving care. Read Dr.

Hmm. PCMA recently claimed that "Drug companies alone set and raise drug prices and can lower the list prices at any time." That's misleading, simplistic, and not quite accurate. But it does raise an interesting question: who, exactly, sets the prices for private label drugs from.

🚨𝐌𝐚𝐫𝐤𝐮𝐩 𝐌𝐚𝐝𝐧𝐞𝐬𝐬 2025: 𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐬, 𝐈𝐧𝐬𝐮𝐫𝐞𝐫𝐬, 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐁𝐫𝐨𝐤𝐞𝐧 𝐁𝐮𝐲-𝐚𝐧𝐝-𝐁𝐢𝐥𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 𝐟𝐨𝐫 𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬. New on Drug Channels: We examine how much hospitals are reimbursed by Aetna, Anthem, Cigna, and UnitedHealthcare

𝐏𝐁𝐌 𝐌𝐚𝐫𝐤𝐞𝐭 𝐂𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧: 𝐀𝐧𝐨𝐭𝐡𝐞𝐫 𝐋𝐨𝐨𝐤. Per @AmerMedicalAssn, analysis of #PBM market share by covered lives, the top 4 PBMs control about two-thirds of the market across these functions: . • Rebate Negotiation . • Retail Network Management. •

🔍 𝐈𝐧𝐭𝐫𝐢𝐠𝐮𝐢𝐧𝐠 𝐍𝐞𝐰 𝐃𝐚𝐭𝐚 𝐨𝐧 𝐑𝐞𝐭𝐚𝐢𝐥 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬 (2010–2023). Fresh insights from a new analysis of U.S. #pharmacy openings and closures:. • Chain Pharmacies: From 2010 to 2015, total chain locations grew. But since 2016, closures have

🚨 𝐈𝐂𝐘𝐌𝐈: 𝐀𝐞𝐭𝐧𝐚'𝐬 𝐖𝐡𝐢𝐭𝐞 𝐁𝐚𝐠𝐠𝐢𝐧𝐠 𝐌𝐨𝐯𝐞: 𝐒𝐚𝐯𝐢𝐧𝐠 𝐌𝐨𝐧𝐞𝐲 𝐨𝐫 𝐒𝐡𝐢𝐟𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐠𝐢𝐧?. On July 1, @Aetna ($CVS) moved five provider-administered drugs—Evenity, Ocrevus/Ocrevus Zunovo, Remicade, Tezspire, and Xolair—from medical benefit to